Authors: Reigner, B Blesch, K Weidekamm, E

Citation: B. Reigner et al., Clinical pharmacokinetics of capecitabine, CLIN PHARMA, 40(2), 2001, pp. 85-104

Authors: Schuller, J Cassidy, J Dumont, E Roos, B Durston, S Banken, L Utoh, M Mori, K Weidekamm, E Reigner, B

Citation: J. Schuller et al., Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients, CANC CHEMOT, 45(4), 2000, pp. 291-297

Authors: Twelves, C Glynne-Jones, R Cassidy, J Schuller, J Goggin, T Roos, B Banken, L Utoh, M Weidekamm, E Reigner, B

Citation: C. Twelves et al., Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites, CLIN CANC R, 5(7), 1999, pp. 1696-1702

Authors: Cassidy, J Twelves, C Cameron, D Steward, W O'Byrne, K Jodrell, D Banken, L Goggin, T Jones, D Roos, B Bush, E Weidekamm, E Reigner, B

Citation: J. Cassidy et al., Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients, CANC CHEMOT, 44(6), 1999, pp. 453-460

Authors: Reigner, B Clive, S Cassidy, J Jodrell, D Schulz, R Goggin, T Banken, L Roos, B Utoh, M Mulligan, T Weidekamm, E

Citation: B. Reigner et al., Influence of the antacid Maalox on the pharmacokinetics of capecitabine incancer patients, CANC CHEMOT, 43(4), 1999, pp. 309-315